ZD4054 With Positron Emission Tomography/Magnetic Resonance Imaging (PET/MRI) for Prostate Cancer

Inclusion Criteria

• •1. Men \> 18 years of age.
• •2. Histologically proven adenocarcinoma of the prostate.
• •3. Presence of radiographic bone metastasis with at least one which is amenable to serial imaging using MRI/PET imaging.
• •4. Patients must have evidence of progressive disease by either radiographic progression or a rising PSA within 4 weeks prior to registration.
• •5. Patients must have had prior treatment with bilateral orchiectomy or other primary androgen-deprivation therapy.
• •6. For patients previously treated with flutamide (Eulexin), Nilutamide (Nilandron), or bicalutamide (Casodex): Patients must have discontinued flutamide \> 4 weeks prior to registration with continued evidence of progressive disease. For bicalutamide or nilutamide, patients must have discontinued the drug \> 6 weeks prior to registration with evidence of progressive disease.
• •7. Prior therapy is permitted as long as it was given \> 4 weeks prior to registration, and evidence for disease progression is met.
• •8. Patients must not have had prior radiotherapy \< 4 weeks prior to registration.
• •9. Prior use of bisphosphonates allowed only if started at least 12 or more weeks prior to registration (can continue current dose/schedule while on study).
• •10. Patient cannot have had prior Strontium 89, Samarium 153, or other radioisotope.
• •11. No concurrent use of estrogen, or estrogen-like agents
• •12. Patients must have adequate organ function
• •13. ECOG performance status 0-2.